Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreVent-ACaLL
NL-OMON58943Phase 2Active, not recruiting
- Sponsor
- Rigshospitalet
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Venetoclax treatment with Observation (2 arms). Primary endpoint: Optional phase 3 primary endpoint. Started Jun 2024; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON58943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58943.